Skip to main content

PTC Therapeutics, Inc. (PTCT) Stock Analysis

Breakout setup

SellModerate Confidence

Healthcare · Biotechnology

Sell if holding. Engine safety override at $70.11: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10. Specifically: High short interest: 16%; Below-average business quality.

PTC Therapeutics is a global biopharma commercializing rare disease therapies including Sephience (PKU, approved in US/EEA/Japan), Emflaza (DMD, US), Translarna (DMD, non-EEA markets), and Upstaza/Kebilidi (AADC deficiency). Emflaza faces growing generic competition following... Read more

$70.11+13.0% A.UpsideScore 5.6/10#39 of 157 Biotechnology
QualityF-score4 / 9FCF yield-7.19%
Stop $65.09Target $79.11(analyst − 13%)A.R:R 1.3:1
Analyst target$90.93+29.7%14 analysts
$79.11our TP
$70.11price
$90.93mean
$124

Sell if holding. Engine safety override at $70.11: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10. Specifically: High short interest: 16%; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 61, MACD bullish. Score 5.6/10, moderate confidence.

Passes 7/9 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 79d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.

Val6.4Qual3.4Grw10.0Mom5.0Sent7.1Ins3.4Peer3.8Tech5.5Risk4.35.6OVERALL

Recent Developments — PTC Therapeutics, Inc.

Latest news

Generated 2026-05-20T20:21:21Z.

Thesis

Rewards
No bull case signals
Risks
Concentration risk — Product: Emflaza
Concentration risk — Product: Translarna
Quality below floor (3.4 < 4.0)

Key Metrics

P/E (TTM)—
P/E (Fwd)25.2
Mkt Cap$5.8B
EV/EBITDA-318.1
Profit Mgn-22.6%
ROE—
Rev Growth-76.8%
Beta0.53
DividendNone
Rating analysts22

Quality Signals

Piotroski F4/9

Options Flow

P/C0.52bullish
IV55%elevated
Max Pain$30-57.2% vs spot

Concentration Risks(10-K Item 1A)

  • HIGHProductEmflaza
    10-K Item 1: 'we have seen an increase in competition from generics, which has, and we expect will continue to have, a negative impact on Emflaza net product revenue'
  • HIGHProductTranslarna
    10-K Item 1A: 'There is a substantial risk that as a result of the EC's adoption of the CHMP's negative opinion we will lose a significant portion of our ability to generate revenue from sales of Translarna in the EEA.'

Material Events(8-K, last 90d)

  • 2026-03-25Item 5.02LOW
    Jessica Chutter appointed to the Board as a Class I director (term expiring at 2026 Annual Meeting), filling a vacancy. No officer departure. Routine board appointment.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

2 floor-breakers·1 ceiling hit

Unprofitable operations — net margin -22.6%. Quality floor flags this regardless of sector context.static

Roa
0.0
Net Margin
0.0
Fcf Quality
0.0
Gross Margin
3.4
Piotroski F
4.4
Moat
4.5
Operating Margin
6.6
Current Ratio
8.3
Cash-burning: FCF -51% of revenueNo competitive moat

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Growth Rank
1.3
Quality Rank
2.7
Value Rank
6.2
GatesA.R:R 1.3 < 1.5@spotMomentum 5.0<5.5 (soft — BUY_NOW allowed but watch)Momentum 5.0>=4.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 79d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARBreakoutSuitability: Moderate
RSI
61 · Neutral
↑ 20D MA↑ 50D MA↑ 200D MAGOLDEN CROSSSupport $63.18Resistance $79.91

Price Targets

$65
$79
A.Upside+12.8%
A.R:R1.3:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! Quality below floor (3.4 < 4.0)
! Reward/Risk 1.3:1 at current price — below 1.5:1 minimum

Earnings

B
B
B
M
3/4 beats
Next Earnings2026-08-06 (79d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is PTCT stock a buy right now?

Sell if holding. Engine safety override at $70.11: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10. Specifically: High short interest: 16%; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 61, MACD bullish. Prior stop was $65.09. Score 5.6/10, moderate confidence.

What is the PTCT stock price target?

Take-profit target: $79.11 (+13.0% upside). Prior stop was $65.09. Stop-loss: $65.09.

What are the risks of investing in PTCT?

Concentration risk — Product: Emflaza; Concentration risk — Product: Translarna; Quality below floor (3.4 < 4.0).

Is PTCT overvalued or undervalued?

PTC Therapeutics, Inc. trades at a P/E of N/A (forward 25.2). TrendMatrix value score: 6.4/10. Verdict: Sell.

What do analysts say about PTCT?

22 analysts cover PTCT with a consensus score of 3.8/5. Average price target: $91.

What does PTC Therapeutics, Inc. do?PTC Therapeutics is a global biopharma commercializing rare disease therapies including Sephience (PKU, approved in...

PTC Therapeutics is a global biopharma commercializing rare disease therapies including Sephience (PKU, approved in US/EEA/Japan), Emflaza (DMD, US), Translarna (DMD, non-EEA markets), and Upstaza/Kebilidi (AADC deficiency). Emflaza faces growing generic competition following orphan exclusivity expiry in February 2024, and Translarna has lost its EEA marketing authorization following a 2025 EC negative opinion.

Related stocks: AUPH (Aurinia Pharmaceuticals Inc) · INCY (Incyte Corporation) · ARGX (argenx SE) · HALO (Halozyme Therapeutics, Inc.) · HRMY (Harmony Biosciences Holdings, I)